Revance Launches DAXXIFY Streaming TV Campaign to Expand Aesthetic Treatment Awareness
Key Takeaways
- Revance has launched "Relatable Moments," a new direct-to-consumer streaming television campaign promoting DAXXIFY (daxibotulinumtoxinA-lanm) for moderate to severe glabellar lines.
- The campaign debuted November 16, 2026, across major streaming and social platforms, including Netflix, Hulu, Disney+, Prime Video, HBO Max, YouTube, Meta, and TikTok.
- The campaign features a real DAXXIFY patient and focuses on peer-to-peer conversations about aesthetic treatments rather than clinical efficacy data.

Revance has launched a new direct-to-consumer advertising campaign for DAXXIFY (daxibotulinumtoxinA-lanm), its FDA-approved injectable neuromodulator for the temporary improvement of moderate to severe glabellar lines in adults.
The campaign, titled "Relatable Moments," debuted November 16, and marks an expansion of the company's consumer outreach through streaming television and digital platforms.
The initiative emphasizes conversations among women about cosmetic injectable treatments, reflecting Revance's strategy to increase awareness of DAXXIFY through personal experiences and word-of-mouth recommendations.
The advertisement features four women interacting in a restroom, including Maya, an actual DAXXIFY patient who discusses her treatment experience. The campaign portrays informal exchanges about aesthetic procedures and encourages viewers to discuss DAXXIFY with their aesthetic providers.
DAXXIFY Campaign Expands Across Streaming and Social Platforms
According to Revance, the campaign will appear on Netflix, Prime Video, Hulu, Disney+, HBO Max, YouTube, Meta, and TikTok, extending its reach across streaming television and social media.
"Today's patients are not gatekeeping the aesthetic treatments they love, and 'Relatable Moments' was created to celebrate exactly that," said Adelle Walker, chief marketing officer of aesthetics at Revance.
DAXXIFY is a peptide-formulated botulinum toxin type A product approved for treating moderate to severe frown lines between the eyebrows in adults. Its prescribing information includes a boxed warning concerning distant spread of toxin effects, which can cause serious swallowing and breathing difficulties.
Revance described DAXXIFY as the fastest-growing neurotoxin in the United States, citing proprietary market-tracking data. The announcement did not provide independently verifiable sales figures, audience projections, or campaign performance metrics.
The launch represents a consumer marketing initiative rather than a new indication, regulatory approval, or clinical development for DAXXIFY.
Reference
Revance. Revance debuts DAXXIFY streaming TV spot, "Relatable Moments," bringing honest aesthetics conversations to a wider audience. PR Newswire. Published November 16, 2026. Accessed November 16, 2026. https://www.prnewswire.com/news-releases/revance-debuts-daxxify-streaming-tv-spot-relatable-moments-bringing-honest-aesthetics-conversations-to-a-wider-audience-302939452.html